Seaport Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to advancing a pipeline of transformative medicines for neuropsychiatric disorders. The company utilizes its proprietary Glyph platform, a specialized drug-delivery technology designed to leverage the body’s natural lymphatic transport system. This approach allows for the oral administration of therapeutics that would otherwise be limited by poor absorption or significant first-pass metabolism in the liver, potentially reducing side effects and enhancing therapeutic reach to the brain. Seaport’s clinical pipeline is focused on addressing significant unmet needs in mental health. Its lead candidates include SPT-300, an oral prodrug of allopregnanolone being developed for the treatment of major depressive disorder (MDD) with postpartum depression; SPT-320, an oral prodrug of agomelatine intended for generalized anxiety disorder (GAD); and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen being developed for various neuropsychiatric conditions. Founded by PureTech Health and led by an experienced management team with a track record in CNS drug development, Seaport Therapeutics aims to redefine the treatment landscape for depression, anxiety, and other neurological conditions by optimizing the pharmacological profiles of proven molecules through innovative lymphatic targeting.
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
...and much more!